Wolfe Research analyst Andy Chen reiterated an Outperform rating and $98.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'June 12, 2026 2:53 PM Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'June 10, 2026 10:38 AM Dianthus Therapeutics (DNTH) Reiterated at Buy by Stifel June 10, 2026 7:21 AM